

# Nick J Edwards

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5760538/publications.pdf>

Version: 2024-02-01

34  
papers

7,762  
citations

172207

29  
h-index

344852

36  
g-index

43  
all docs

43  
docs citations

43  
times ranked

12080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
2	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
3	Mapping immune variation and var gene switching in naive hosts infected with <i>Plasmodium falciparum</i> . <i>ELife</i> , 2021, 10, .	2.8	22
4	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
5	Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. <i>Frontiers in Immunology</i> , 2021, 12, 694759.	2.2	22
6	Controlled human malaria infection with a clone of <i>Plasmodium vivax</i> with high-quality genome assembly. <i>JCI Insight</i> , 2021, 6, .	2.3	22
7	ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. <i>Nature</i> , 2020, 586, 578-582.	13.7	840
8	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 467-478.	6.3	2,080
9	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet</i> , The, 2020, 396, 1979-1993.	6.3	1,196
10	A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. <i>Science Advances</i> , 2020, 6, eaba8399.	4.7	89
11	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. <i>Vaccines</i> , 2019, 7, 40.	2.1	19
12	A defined mechanistic correlate of protection against <i>Plasmodium falciparum</i> malaria in non-human primates. <i>Nature Communications</i> , 2019, 10, 1953.	5.8	51
13	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	2.9	51
14	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559.	3.7	34
15	Human vaccination against <i>Plasmodium vivax</i> Duffy-binding protein induces strain-transcending antibodies. <i>JCI Insight</i> , 2017, 2, .	2.3	78
16	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. <i>JCI Insight</i> , 2017, 2, .	2.3	109
17	Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts. <i>PLoS Pathogens</i> , 2017, 13, e1006108.	2.1	104
18	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against <i>Plasmodium falciparum</i> Infection in Adults in Senegal. <i>PLoS ONE</i> , 2016, 11, e0167951.	1.1	46

#	ARTICLE	IF	CITATIONS
19	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01<sub>B</sub>With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. <i>Journal of Infectious Diseases</i> , 2016, 214, 772-781.	1.9	96
20	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
21	Demonstration of the Blood-Stage <i>Plasmodium falciparum</i> Controlled Human Malaria Infection Model to Assess Efficacy of the <i>P. falciparum</i> Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. <i>Journal of Infectious Diseases</i> , 2016, 213, 1743-1751.	1.9	95
22	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naïve Individuals. <i>Journal of Infectious Diseases</i> , 2015, 211, 1076-1086.	1.9	110
23	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. <i>Science Translational Medicine</i> , 2015, 7, 286re5.	5.8	113
24	Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. <i>Vaccine Journal</i> , 2014, 21, 901-903.	3.2	12
25	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naïve to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003.	3.7	49
26	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836.	5.8	256
27	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 340-345.	1.9	53
28	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	1.1	80
29	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781.	1.9	194
30	ChAd63-MVA vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	3.7	196
31	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the <i>Plasmodium falciparum</i> Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. <i>PLoS ONE</i> , 2012, 7, e31208.	1.1	157
32	Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. <i>PLoS ONE</i> , 2012, 7, e38434.	1.1	66
33	A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. <i>PLoS ONE</i> , 2012, 7, e40385.	1.1	301
34	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011, 6, e22271.	1.1	84